Original articles

One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T Vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine

Shabir Ahmed Madhi, Clare Cutland, Stephanie Jones, Michelle Groome, Esteban Ortiz


Objective. To assess the immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Hib polysaccharide-conjugate vaccine booster.
Design, setting and participants. A DTaP-IPV//PRP~T vaccine (Pentaxim, a Sanofi Pasteur AcXim family vaccine) was given to 182 healthy children in South Africa at 18 - 19 months of age following priming with the same vaccine plus a monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age.
Outcome measures. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titres (GMTs) and concentrations (GMCs) were assessed before, and 1 month after, the booster dose. Safety was assessed using parental reports.
Results. One month after primary vaccination, at least 94.3% of participants were seroprotected against tetanus (≥0.01 IU/ml), diphtheria (≥0.01 IU/ml), poliovirus (≥8 1/dil) and Haemophilus influenzae type b (Hib) infection (≥0.15 µg/ml). Before the booster dose, the SP rates ranged from 65.7% to 100%. One month after the booster dose, SP rates were 97.7% for Hib (anti-PRP titre 1.0 g/ml), 100.0% for diphtheria (0.1 IU/ml) and 100% for tetanus (0.1 IU/ml) and poliovirus types 1, 2, 3 (8 1/dil). At least 95.7% of participants had 4 fold post-booster increases in anti-pertussis antibody titres. GMTs increased from 11.21 to 465.51 EU/ml and from 12.89 to 520.35 EU/ml for anti-PT and anti-FHA respectively. Anti-PRP GMT increased from 0.35 to 47.01 g/ml. The DTaP-IPV//PRP~T vaccine booster was well tolerated, with fever ≥39.0°C in only 1.7% of participants.
Conclusions. Antibody persistence following priming was satisfactory. The pentavalent DTaP-IPV//PRP~T vaccine booster was highly immunogenic and well tolerated.

Authors' affiliations

Shabir Ahmed Madhi,

Clare Cutland,

Stephanie Jones,

Michelle Groome,

Esteban Ortiz,

Full Text



pentavalent; combined vaccine; acellular pertussis; immunogenicity; safety; booster;

Cite this article

South African Medical Journal 2011;101(12):879.

Article History

Date submitted: 2011-05-19
Date published: 2011-11-28

Article Views

Abstract views: 2153
Full text views: 5124

Comments on this article

*Read our policy for posting comments here